May be useful for predicting early recurrence of disease in women who have been treated for carcinoma of the breast. FDA approved for serial testing in women with prior stage II or III breast cancer who are clinically free of disease. This test should be used in conjunction with other clinical methods used for the early detection of recurrence.
Reference values have not been established for patients that are less than 18 years of age. Female: < or = 38 U/mL; Male: < or = 38 U/mL (use not defined).
Not useful as a screening test for carcinoma of the breast. For research use only in male patients.
2 - 3 days
- BREAST CARCINOMA-ASSOC ANTIGEN
Test sent to Mayo Medical Laboratories.